Form 10-Q
OCULAR THERAPEUTIX, INC filed this Form 10-Q on 05/10/2019
Document Outline
Entire Document (11644.5 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - Ocular Therapeutix, Inc.
Page 3 - FORWARD-LOOKING STATEMENTS
Page 4 - N/A
Page 5 - PART I FINANCIAL INFORMATION
Page 6 - Ocular Therapeutix, Inc.
Page 7 - Ocular Therapeutix, Inc.
Page 8 - Ocular Therapeutix, Inc.
Page 9 - Ocular Therapeutix, Inc.
Page 10 - Ocular Therapeutix, Inc.
Page 11 - Unaudited Interim Financial Information
Page 12 - Derivative Liability
Page 13 - Recently Issued and Adopted Accounting Pronouncements
Page 14 - 3. Fair Value of Financial Assets and Liabilities
Page 15 - 5. Convertible Notes
Page 16 - N/A
Page 17 - 6. Income Taxes
Page 18 - 8. Notes Payable
Page 19 - 9. Common Stock
Page 20 - 10. Net Loss Per Share
Page 21 - 11. Stock-Based Awards
Page 22 - Stock-based Compensation
Page 23 - Financial Terms
Page 24 - Collaboration Agreement
Page 25 - Shareholder Derivative Litigation
Page 26 - Terry Kelly v. Sawhney et al.CorwinMaderaCorwin
Page 27 - 14. Leases
Page 28 - 15. Subsequent Events
Page 29 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 30 - Glaucoma Programs
Page 31 - OTX-TIC (intracanalicular travoprost implant)
Page 32 - ReSureSealant
Page 33 - Additional Potential Areas for Growth
Page 34 - Financial Operations Overview
Page 35 - N/A
Page 36 - Selling and Marketing Expenses
Page 37 - Critical Accounting Policies and Significant Judgments and Estimates
Page 38 - Results of Operations
Page 39 - Selling and Marketing Expenses
Page 40 - Liquidity and Capital Resources
Page 41 - Cash Flows
Page 42 - Funding Requirements
Page 43 - N/A
Page 44 - Contractual Obligations and Commitments
Page 45 - N/A
Page 46 - N/A
Page 47 - Off-Balance Sheet Arrangements
Page 48 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 49 - PART II OTHER INFORMATION
Page 50 - Angel Madera v. Sawhney et al.CorwinRobert Corwin v. Sawhney et al.Corwin
Page 51 - Terry Kelly v. Sawhney et al.CorwinMadera Corwin
Page 52 - N/A
Page 53 - We will need substantial additional funding. If we are unable to raise capital when needed, we could
Page 54 - N/A
Page 55 - We have included a paragraph relating to our ability to continue as a going concern in the footnotes
Page 56 - Our limited operating history may make it difficult for our stockholders to evaluate the success of
Page 57 - We have broad discretion in the use of our available cash and other sources of funding and may not u
Page 58 - If clinical trials of our intracanalicular insert product candidates or any other product candidate
Page 59 - N/A
Page 60 - We have conducted, and may in the future conduct, clinical trials for product candidates at sites ou
Page 61 - If we experience any of a number of possible unforeseen events in connection with our clinical trial
Page 62 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 63 - If serious adverse or unacceptable side effects are identified during the development or commerciali
Page 64 - We may expend our limited resources to pursue a particular product, product candidate or indication
Page 65 - If our sole clinical manufacturing facility is damaged or destroyed or production at this facility i
Page 66 - Risks Related to Commercialization
Page 67 - If we are unable to establish and maintain adequate sales, marketing and distribution capabilities,
Page 68 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 69 - DEXTENZA, ReSure Sealant and any product candidates for which we obtain marketing approval may becom
Page 70 - N/A
Page 71 - Product liability lawsuits against us could cause us to incur substantial liabilities and to limit c
Page 72 - We have entered into collaborations with third parties to develop certain product candidates, and in
Page 73 - N/A
Page 74 - If we are not able to establish additional collaborations, we may have to alter our development and
Page 75 - Risks Related to Our Intellectual Property
Page 76 - inter partes
Page 77 - If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act
Page 78 - Third parties may initiate legal proceedings alleging that we are infringing their intellectual prop
Page 79 - We may be subject to claims by third parties asserting that our employees or we have misappropriated
Page 80 - If we are unable to protect the confidentiality of our trade secrets, our business and competitive p
Page 81 - Failure to obtain marketing approval in foreign jurisdictions would prevent our products or product
Page 82 - Even if we, or any current or future collaborators, obtain marketing approvals for our product candi
Page 83 - We may be subject to substantial penalties if we fail to comply with regulatory requirements or if w
Page 84 - Our relationships with healthcare providers, physicians and third-party payors will be subject, dire
Page 85 - N/A
Page 86 - Under the Cures Act and the Trump Administration s regulatory reform initiatives, the FDA s policies
Page 87 - N/A
Page 88 - N/A
Page 89 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 90 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 91 - The comprehensive tax reform bill enacted in 2017 could adversely affect our business and financial
Page 92 - We expect to expand our development, regulatory and manufacturing capabilities and potentially imple
Page 93 - Provisions in our corporate charter documents and under Delaware law could make an acquisition of ou
Page 94 - An active trading market for our common stock may not be sustained.
Page 95 - Sales of a substantial number of shares of our common stock in the public market could cause our sto
Page 96 - We incur increased costs as a result of operating as a public company, and our management is now req
Page 97 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 98 - Exhibit Index
Page 99 - N/A
Page 100 - SIGNATURES
Subdocument 2 - EX-10.4 - EX-10.4
Page 1 - Exhibit 10.4
Page 2 - Term
Page 3 - Rent TaxMonthly Gross Rent
Page 4 - Payments of Rent
Page 5 - Security Deposit
Page 6 - Time Allowances; Consents
Page 7 - Sublessee Parties
Page 8 - Right to Cure Defaults:
Page 9 - Brokers
Page 10 - As-Is; No Warranties
Page 11 - Exhibit C-1Personal PropertyExhibit C Bill of Sale
Page 12 - Miscellaneous:
Page 13 - Limitation of Liability
Page 14 - Intentionally Omitted.
Page 15 - Signature Page to Sublease
Page 16 - Exhibit A
Page 17 - N/A
Page 18 - TABLE OF CONTENTS
Page 19 - TABLE OF CONTENTS
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - SIGNATURES
Page 48 - N/A
Page 49 - EXHIBIT
Page 50 - N/A
Page 51 - N/A
Page 52 - EXHIBIT
Page 53 - N/A
Page 54 - EXHIBIT
Page 55 - N/A
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - N/A
Page 63 - N/A
Page 64 - N/A
Page 65 - N/A
Page 66 - N/A
Page 67 - N/A
Page 68 - N/A
Page 69 - N/A
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - EXHIBIT
Page 82 - N/A
Page 83 - N/A
Page 84 - EXHIBIT
Page 85 - N/A
Page 86 - EXHIBIT
Page 87 - N/A
Page 88 - N/A
Page 89 - Exhibit B
Page 90 - Exhibit C
Page 91 - Exhibit C-1
Subdocument 3 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 6 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer